Japan Chemical Daily

Japan's leading chemical industry newspaper

Log In

Sumitomo Dainippon Pharma Targets GMP-Based Mass Production of Cellular Medicine

Filed Under: Industry, Pharma Tagged With: , , , , , , ,

Sumitomo Dainippon Pharma Co. Ltd. (TYO:4506) is working toward the mass production of cellular pharmaceuticals for regenerative medicines derived from…...

Please subscribe to read the full story.

Subscribe Free Trial

Related Articles:

Teijin Expands Health Care Operations for Bone and Joint Diseases
Teijin Expands Health Care Operations for Bone and Joint…
Chemical and Material Companies Look to Take Pharmaceutical Operations to the Next Stage
Chemical and Material Companies Look to Take Pharmaceutical…
Mitsubishi Chemical Holdings to Turn Mitsubishi Tanabe Pharma Into Wholly Owned Subsidiary
Mitsubishi Chemical Holdings to Turn Mitsubishi Tanabe…
Asahi Kasei Works on New iPS Treatments for Orthopedic Sector
Asahi Kasei Works on New iPS Treatments for Orthopedic…
Sumitomo Chemical President Keiichi Iwata Lays out Plan to Get Core Operating Income to 280B Yen
Sumitomo Chemical President Keiichi Iwata Lays out Plan to…
Mitsubishi Chemical to Produce Regenerative Medicine Materials From Plants
Mitsubishi Chemical to Produce Regenerative Medicine…